Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/1613

Title: Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials.
Authors: Liberman, U.
Hochberg, M.
Shah, A.
Lin, Jie
Chattopadhyay, A.
Ross, P.
Issue Date: 2006
Publisher: Blackwell
Abstract: A number of antiresorptive agents reduce the risk of vertebral fractures, but few have shown consistent effects on hip and other non-spine fractures. Meta-analysis provides a more precise estimate than individual trials when results are consistent across pooled trials. Earlier meta-analyses summarised the results for vertebral and non-spine fractures. New data have emerged for hormone therapy (HT), alendronate (ALN), risedronate (RIS) and ibandronate (IBN). We surveyed recent reports of randomised, placebo-controlled trials with non-spine and/or hip fracture data, and used meta-analysis where appropriate to test for heterogeneity and derive pooled estimates. The magnitude of effect on hip fracture appears to be similar to that for non-spine fracture for each drug, but differs among drugs. Based on the current data, ALN reduces the risk of hip and non-spine fracture by 49–55%, HT by 25–36% and RIS by 26–27%. There is insufficient and/or inconsistent evidence of an effect on these fractures for IBN, calcitonin and raloxifene.
URI: http://hdl.handle.net/1942/1613
DOI: 10.1111/j.1742-1241.2006.01148.x
ISI #: 000241190700012
ISSN: 1368-5031
Category: A1
Type: Journal Contribution
Validation: ecoom, 2007
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.